Intravenous immunoglobulin showed no clear difference in serious adverse events compared with prednisolone (moderate certainty).
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Summary of findings table ‐ Immunoglobulins showed no clear difference in serious adverse events compared with placebo (low certainty).
Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).
Summary of findings table ‐ Immunoglobulins showed no clear difference in adverse events of any severity or seriousness compared with placebo (low certainty).
Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).
Anti‐IL13 or anti‐IL4 agents showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
It is very uncertain whether cerebrospinal fluid filtration changes participants with 1 or more serious adverse events compared with plasma exchange (very low certainty).
Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).